JP5576485B2 - 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール - Google Patents

新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール Download PDF

Info

Publication number
JP5576485B2
JP5576485B2 JP2012522131A JP2012522131A JP5576485B2 JP 5576485 B2 JP5576485 B2 JP 5576485B2 JP 2012522131 A JP2012522131 A JP 2012522131A JP 2012522131 A JP2012522131 A JP 2012522131A JP 5576485 B2 JP5576485 B2 JP 5576485B2
Authority
JP
Japan
Prior art keywords
formula
compound
lower alkyl
amino
lower alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012522131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500304A5 (enExample
JP2013500304A (ja
Inventor
ポールマン，イェンス
バッハマン，フェリクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica AG
Original Assignee
Basilea Pharmaceutica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica AG filed Critical Basilea Pharmaceutica AG
Publication of JP2013500304A publication Critical patent/JP2013500304A/ja
Publication of JP2013500304A5 publication Critical patent/JP2013500304A5/ja
Application granted granted Critical
Publication of JP5576485B2 publication Critical patent/JP5576485B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2012522131A 2009-07-27 2010-07-26 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール Expired - Fee Related JP5576485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09166469 2009-07-27
EP09166469.8 2009-07-27
PCT/EP2010/060803 WO2011012577A1 (en) 2009-07-27 2010-07-26 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Publications (3)

Publication Number Publication Date
JP2013500304A JP2013500304A (ja) 2013-01-07
JP2013500304A5 JP2013500304A5 (enExample) 2013-05-30
JP5576485B2 true JP5576485B2 (ja) 2014-08-20

Family

ID=41226617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012522131A Expired - Fee Related JP5576485B2 (ja) 2009-07-27 2010-07-26 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール

Country Status (24)

Country Link
US (1) US8802858B2 (enExample)
EP (1) EP2459553B1 (enExample)
JP (1) JP5576485B2 (enExample)
KR (1) KR101758400B1 (enExample)
CN (1) CN102471329B (enExample)
AU (1) AU2010277688B2 (enExample)
BR (1) BR112012001817B8 (enExample)
CA (1) CA2767875C (enExample)
CY (1) CY1115809T1 (enExample)
DK (1) DK2459553T3 (enExample)
EA (1) EA021380B1 (enExample)
ES (1) ES2524119T3 (enExample)
HR (1) HRP20141120T1 (enExample)
IL (1) IL217195A (enExample)
MX (1) MX336240B (enExample)
NZ (1) NZ597376A (enExample)
PL (1) PL2459553T3 (enExample)
PT (1) PT2459553E (enExample)
RS (1) RS53679B1 (enExample)
SI (1) SI2459553T1 (enExample)
TW (1) TWI457337B (enExample)
UA (1) UA106763C2 (enExample)
WO (1) WO2011012577A1 (enExample)
ZA (1) ZA201200228B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098203A1 (en) 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
JP6302674B2 (ja) * 2011-01-21 2018-03-28 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのスタスミンの使用
US10222377B2 (en) 2011-01-21 2019-03-05 Basilea Pharmaceutica Ag Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles
JP6295081B2 (ja) * 2011-02-24 2018-03-14 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ フラザノベンゾイミダゾールに対する薬物応答のバイオマーカーとしてのアセチル化チューブリンの使用
JP6334393B2 (ja) 2011-03-29 2018-05-30 バジリア ファルマスーチカ アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ ＡＧ 薬物応答のバイオマーカーとしてのホスホＡｋｔの使用
US9558575B2 (en) 2012-02-28 2017-01-31 Blackberry Limited Methods and devices for selecting objects in images
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
HK1257768A1 (zh) * 2015-10-22 2019-10-25 Basilea Pharmaceutica International AG Eb1作为药物应答的生物标记物的用途
JP2020517608A (ja) * 2017-04-20 2020-06-18 ピーアイ インダストリーズ リミテッドＰｉ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ 新規フェニルアミン化合物
CA3058695A1 (en) * 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
EP3713565A1 (en) 2017-11-20 2020-09-30 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US20220031670A1 (en) 2018-09-20 2022-02-03 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CN111454254B (zh) 2020-04-26 2023-06-02 云白药征武科技(上海)有限公司 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用
CN111423429A (zh) * 2020-05-19 2020-07-17 江西科技师范大学 苯并咪唑联呋咱类系列化合物及其合成方法
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
KR20040084896A (ko) * 2002-02-06 2004-10-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 헤테로아릴 화합물
PT1636215E (pt) * 2003-05-23 2008-04-29 Basilea Pharmaceutica Ag Furazanobenzimidazoles
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis

Also Published As

Publication number Publication date
PL2459553T3 (pl) 2015-03-31
PT2459553E (pt) 2014-11-24
AU2010277688B2 (en) 2013-12-05
ES2524119T3 (es) 2014-12-04
IL217195A (en) 2014-03-31
BR112012001817B8 (pt) 2021-05-25
SI2459553T1 (sl) 2015-01-30
EP2459553A1 (en) 2012-06-06
BR112012001817B1 (pt) 2020-09-29
CA2767875A1 (en) 2011-02-03
BR112012001817A2 (pt) 2016-03-15
CN102471329A (zh) 2012-05-23
TWI457337B (zh) 2014-10-21
EA201200189A1 (ru) 2012-08-30
US20120264792A1 (en) 2012-10-18
MX2012000611A (es) 2012-01-27
EP2459553B1 (en) 2014-10-01
IL217195A0 (en) 2012-02-29
WO2011012577A1 (en) 2011-02-03
UA106763C2 (uk) 2014-10-10
KR20120055571A (ko) 2012-05-31
US8802858B2 (en) 2014-08-12
CY1115809T1 (el) 2017-01-25
MX336240B (es) 2016-01-13
HRP20141120T1 (hr) 2015-01-30
ZA201200228B (en) 2012-09-26
DK2459553T3 (da) 2014-11-03
TW201107318A (en) 2011-03-01
NZ597376A (en) 2014-01-31
CA2767875C (en) 2016-03-15
CN102471329B (zh) 2014-11-05
AU2010277688A1 (en) 2012-02-09
EA021380B1 (ru) 2015-06-30
KR101758400B1 (ko) 2017-07-14
HK1166316A1 (en) 2012-10-26
JP2013500304A (ja) 2013-01-07
RS53679B1 (sr) 2015-04-30

Similar Documents

Publication Publication Date Title
JP2013500304A (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
US7951957B2 (en) Substituted benzimidazoles and their use for inducing apoptosis
CA2526026C (en) Furazanobenzimidazoles
AU2019331665A1 (en) Heterocyclic compounds as AHR modulators
JP6927959B2 (ja) ベンジリデングアニジン誘導体と化学療法剤の併用による癌の治療方法
JP2014532656A (ja) 炎症および免疫関連用途のための化合物
JP7397072B2 (ja) ウイルス感染を処置するための２，６－ジメチル－Ｎ－（（ピリジン－４－イル）メチル）イミダゾ［１，２－ｂ］ピリダジン－８－アミンおよび２，５－ジメチル－Ｎ－［（ピリジン－４－イル）メチル］ピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体
HK1166316B (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
JP7616609B2 (ja) Ｒｎａウイルス感染症を処置する為のアリール－ｎ－アリール誘導体
HK40063832B (en) Aryl-n-aryl derivatives for treating a rna virus infection
WO2024099226A1 (zh) 含苯联杂芳基的二氢喋啶酮衍生物及其用途
JP2008308434A (ja) １，３−ベンゾチアジノン誘導体およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140703

R150 Certificate of patent or registration of utility model

Ref document number: 5576485

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees